MVP方案治疗晚期非小细胞肺癌的临床观察

Therapeutic Effects of MVP Regimen for Treatment of Advanced Non small Cell Lung Cancer

目的 观察采用由丝裂霉素 (MMC)、长春花碱酰胺 (VDS)、顺铂 (DDP )组成的MVP方案治疗 76例晚期非小细胞癌 (NSCLC )的疗效和不良反应。 方法 MMC 8mg/m2 ,静脉注射 ,第 1天 ;VDS 2 .5～ 3 .0mg/m2 ,静脉注射 ,第 1、8天 ;DDP 40～ 5 0mg/m2 ,静脉滴注 ,第 2、3天 ;3～ 4周为 1个周期 ,连用 2～ 3个周期。结果 CR 1例 ,PR 2 5例 ,总有效率为 38.16 %。初治有效率为 44.0 0 % ,复治有效率为 15 .38%。鳞癌有效率为 38.46 % ,腺癌有效率为 37.90 %。中位缓解期为 4个月 ,中位生存期为 8个月。该方案的剂量限制性毒性为白细胞下降 ,Ⅲ、Ⅳ度白细胞下降率为 39.83 %。结论 采用MVP方案治疗晚期非小细胞肺癌的有效率较高 ,不良反应可以耐受 ,价格适中 。

Objective To evaluate the results of combination chemotherapy with mitomycin(MMC),vindesine(VDS),and cisplatin(DDP) in patients with advanced non small cell lung cancer(NSCLC).Methods 76 cases of advanced NSCLC were treated with MVP regimen in this study.26 patients received prior chemotherapy while 50 did not.Results Complete response was observed in one and partial response in 25 patients,overall response rate(RR) was 38.16%.The RR was significantly higher in the priveously untreated patients(44.0%) compared with the pretreated patients(15.38%).The RR was not significantly different between squamous cell carcinoma(38.46%) and adenocarcinoma(37.93%).The median response duration was 4 months.The median survival period was 8 months.The dose limiting toxicity was neutropenia,which was grade Ⅲ and Ⅳ in 39.83% of the patients.Conclusion A higher response rate is attainable in patients with advanced NSCLC by treatment of MVP regimen.